



We want to save patients with severe cancer and autoimmune diseases  
*Clinical investigations with our lead antibody CAN04 to our proprietary target*


Göran Forsberg, CEO

October 2020

# Safe Harbour Statement

Statements in the Investor Presentation, including those regarding the possible or assumed future or other performance of the Company or its industry or other trend projections, constitute forward-looking statements. By their nature, forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors as they relate to events and depend on circumstances that will or may occur in the future, whether or not outside the control of the Company. No assurance is given that such forward-looking statements will prove to be correct. Prospective investors should not place undue reliance on forward-looking statements. They speak only as at the date of this Investor Presentation and the Company undertakes no obligation to update these forward-looking statements. Past performance does not guarantee or predict future performance. Moreover, the Company undertakes no obligation to review, update or confirm expectations or estimates or to release any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of the Investor Presentation.

# Cantargia – Opportunity to save lives and create value



- Potentially more effective treatment against novel target in clinically validated pathway
- Right team and clear plan to position our projects and maximize value
- First in class platform technology against novel target

# Cantargia at a glance



## Unique immunotherapy antibody CAN04 in phase IIa clinical development

- Positive interim data set with response rates higher than historic data
- Further phase II milestones during 2020



## Platform with many potential therapeutic areas

- IL1RAP found on most solid tumor forms and leukemia
- IL1RAP signalling (IL-1, IL-33 and IL-36) described in large number of autoimmune/inflammatory diseases



## Vision of becoming an important part in future cancer treatments

- Combination therapy strategy based on synergies with established therapies



## Highly relevant research within clinically validated mechanisms

- Focus on opportunities with major unmet medical need



## Robust patent portfolio

- Global patent families on IL1RAP as antibody target in oncology until 2032 and CAN04 until 2035



## Nasdaq Stockholm's main list >6,000 shareholders and long term investors

- Market cap: SEK 4,3bn (USD ~480m) (Oct 5, 2020)
- Cash : SEK 458 MSEK (USD 53m) (30 Jun 2020)


## Current owners (30 June 2020)

4th AP fund	7.8%
Swedbank Robur Funds	7.4%
Alecta	6.6%
1st AP fund	6.3%
Sunstone	5.2%
Öhman Bank S.A.	4.9%
Avanza Pension	4.4%
SEB S.A. (Nordic Cross)	3.0%
Morgan Stanley (HBM)	2.4%
Handelsbanken fonder	2.3%
Others	49.7%

# Cantargia addresses a huge market


## Incidence, Globally 2018

Type of cancer:




## Mortality, Globally 2018

Type of cancer:




## Incidence, Globally 2018

Region:



## Mortality, Globally 2018

Region:




	Lung cancer	Pancreatic cancer
Incidence 2018 (globally)	2,093,876	458,918
Fraction of cancer incidence	13.0%	2.9%
Mortality 2018	1,761,007	432,242
Fraction of cancer mortality	19.9%	4.9%
5 year survival	18.6%	8.5%
Treatment	Surgery, Radiation, Chemotherapy, Immunotherapy	Chemotherapy, Surgery, Radiation

Significant unmet needs in lung and pancreatic cancer




## Lead antibody CAN04


# CAN04 – Mechanism of action




ADCC -Tumor cell death



Reduced activation and infiltration of immunosuppressive cells






Reduced angiogenesis






# CAN04 – Dual anticancer mechanism




- Inhibition of IL-1 signaling:

- ADCC enhanced antibody


NSCLC



IL1 $\alpha$



IL1 $\beta$



Ctrl


**CAN04 blocks tumor inflammation and stimulates direct killing of cancer cells**



# Validating study – Counteracting tumor inflammation

CANTOS trial (n=10,061)

- Canakinumab (Novartis)
- Reduced lung cancer incidence by 67% and death by 77%
- Reduced non-lung cancer death by 37%



- Clinical validation of IL-1 pathway
- Dose/response
- Cantargia's CAN04 has broader MOA

Canakinumab phase III trials

## Adjuvant NSCLC (CANOPY-A)

- 1,500 patients
- After surgery, no mets, placebo control

## First line (CANOPY-1)

- 626 patients
- Untreated locally advanced/metastatic
- Combination Pembro/Platinum doublet

## Second line metastatic (CANOPY-2)


- 240 patients
- Previously treated loc adv/metastatic
- Combinational Docetaxel

## Additional trials

- Renal cell cancer
- Gastroesophageal cancer
- Colorectal cancer
- Non-small cell lung cancer

CANTOS data support CAN04 as well as broader IL1RAP platform activities

# CAN04 – Superior MoA against other IL-1 blocking approaches



Company	Compound	IL-1α	IL-1β	ADCC	Indication/dev phase
Cantargia	CAN04	++	++	++	• Pancreatic cancer, NSCLC phase IIa
Xbiotech/ Janssen	Xilonix	++	—	+	• Autoimmunity, dermatology • Pancreatic cancer, phase I
Novartis	Canakinumab Gevokizumab	—	++	—	• Autoimmunity, registered • NSCLC, phase III • Cancer comb, phase II
Flame Bioscience	FL-101	—	++	—	• NSCLC
Buzzard	Isunakinra	++	++	—	• Cancer phase I
SOBI	Kineret	++	++	—	• Autoimmunity, reg
Regeneron/ Kiniksa	Rilonacept	++	++	—	• Autoimmunity, reg • Pericarditis

## Use of IL1RAP as target for hematological cancers

- Two families
- Valid until 2029/2030
- Granted (EPO, USA, Japan, China)

## Use of IL1RAP as target for solid tumors

- Valid until 2032
  - Granted (EPO\*, Japan, USA, China)
- \*divisional application opposed in Europe

## The product candidate CAN04

- Valid until 2035
- Granted (EPO, USA, China)

Cantargia has strong IP and superior MoA in CAN04

# Positive phase IIa interim combination data

	Initiated	Evaluable	CR/PR	SD	PD	NE
PDAC	10	7	4 <sup>1)</sup>		2 <sup>2)</sup>	1 <sup>2)</sup>
<i>Historical</i>			23%	27%	20%	30%
NSCLC	13	9	6 <sup>1)</sup>	3		
<i>Historical</i>			22-28%	18%	40%	<20%




“After I presented the CAN04 monotherapy data at ASCO 2019, the CANFOUR trial has advanced with the combination therapy. The initial results are very encouraging in non-small cell lung cancer (pretreated with checkpoint inhibitor) and pancreatic cancer and suggest that CAN04 could be a valuable contribution to improve the chemotherapy regimes in these diseases”  
*Prof Ahmad Awada, Institute Jules Bordet, Brussels, Belgium, Coordinating investigator CANFOUR-study*

- By adding CAN04 response rates are higher than historical data using these standard first line chemotherapies alone
- 4 of 7 evaluable patients with metastatic pancreatic cancer (PDAC) showed objective response. 1 additional patient showed pseudoprogression. Pronounced effect of biomarker CA19-9
- 6 of 9 evaluable patients with metastatic non-small cell lung cancer (NSCLC) showed objective response including 1 complete response

**Strong tumor shrinkage in majority of patients**

Note: 1) All patients except 1 PDAC and 1 NSCLC have responses confirmed on second scan. 3 of 4 PDAC patients with objective response has a sustained decrease of >90 % of CA19-9. In NSCLC, 1 patient has a confirmed complete response (CR). 2) 1 patient has ongoing tumor shrinkage after initial progression and a strong reduction in CA19-9. 1 patient terminated after rapid clinical progression without CT-scan

# Tumor shrinkage in NSCLC combination



- 6 of 9 evaluable patients with metastatic non-small cell lung cancer (NSCLC) showed objective response including 1 complete response
- The complete response has lasted more than 1 year
- 5 patients were second line to pembrolizumab monotherapy, 4 patients first line
- No major side effects were observed apart from those expected with chemotherapy or CAN04 alone. Neutropenia frequency higher than expected from chemo (treated with dose reductions/GCSF)

# CAN04 – CANFOUR clinical trial


June  
2019

## CANFOUR RESULTS

PDAC  
Q4  
2020


NSCLC  
Q1  
2020

### Phase I – Dose escalation with safety assessment



- Phase I data presented orally at ASCO 2019
- 22 patients (NSCLC, PDAC, colon cancer)
  - Good safety up to 10 mg/kg
  - Pronounced effect on relevant biomarkers (IL-6, CRP)
  - 9 pts had stable disease up to 6 months

### Phase IIa – Dosage with assessment of therapeutic effect




- Phase IIa (c. 20 centres)
  - Combination with standard therapy (appr 30 pat per arm)
    - Chemonaive patients
    - NSCLC Cisplatin/Gemcitabine
    - PDAC Gemcitabine/nab-paclitaxel
  - Interim analysis higher response rates than historical Monotherapy (20 pat) analysis ongoing (incl biopsies)
  - Late stage patients


*... and new  
complementary trial  
to open in USA*

Generation of data instrumental for next phase of development

# Targeting IL1RAP allows unique synergistic effects with chemotherapy (AACR 2020)



→ Upregulation of both forms of IL-1 in PDX-model treated with Gem/Cis



→ CAN04 increase efficacy of chemotherapy regimes


→ CAN04 counteract weight loss after chemotherapy

Synergy with chemotherapy in line with current development strategy







# Chemotherapy resistance

- Most chemotherapies induce chemoresistance already after a few months of therapy
- Chemotherapy upregulate both IL-1 $\alpha$  and IL-1 $\beta$
- Blocking IL-1 signalling counteracts chemoresistance in preclinical models
- High blood levels of inflammatory cytokines IL-1 and IL-6 leads to poor gemcitabine efficacy in patients
- IL-1 mediated chemoresistance for several classes of chemotherapy
  - Platinum based chemotherapy, 5FU, Gemcitabine



Several lines of evidence suggest CAN04 counteract chemoresistance

# Pancreatic cancer strategy

 Subgroup	 Share (USA)	 Treatment	 Target
Resectable	10%	Surgery	Cure
Locally advanced	29%	Chemotherapy	Response, surgery
Metastatic	52%	Chemotherapy	Response

- USA: Estimate 57,000 cases 2019, 5 year survival rate Resectable 34%, Locally advanced 12%, Metastatic 3%
- Preparation for pivotal trial (in close contact with FDA/EMA) as first line combination therapy with Gem/Abraxane
- Broadening by exploring combination with FOLFIRINOX

**CAN04 focus on first line patients**

# CMC – Long term production strategy

## Technology transfer

- Transfer to Patheon (Groningen, NL)
- Processing method
- Equipment
- Analytical methods

## Scale-up and first batch at new production scale

- Assure GMP compliance
- Product testing to confirm equivalence with previous produced product
- Successful GMP 2,000 liter scale

## Phase III readiness and preparations for registration

- Process characterization and optimization
- Analytical validation
- Process validation batches




The background of the slide is a grayscale composite image. The upper portion shows a close-up of a human face, focusing on the eye and forehead area. The lower portion features a detailed, close-up view of a plant, possibly a flower or seedling, with visible petals and stems. A solid teal horizontal band is positioned across the middle of the image, containing the text.

## CAN04 oncology expansion

# IL1RAP in several cancer with high medical need

IL1RAP



## Cantargia founded based on

- Discovery of IL1RAP on cancer cells
- Antibodies against IL1RAP – antitumor effects
- IP on antibody therapy against IL1RAP

## Primary indications

- Non-small cell lung cancer – NSCLC
- Pancreatic cancer – PDAC

- Biomarker studies ongoing, identify patients most likely to respond
- Opportunity to expand development in additional cancer forms with high unmet medical need

CAN04 development can be expanded to additional indications onwards <sup>19</sup>

# IL1RAP and PD-1 blockade – Rationale for combination study

Chronic tumor inflammation and the tumor microenvironment are immune suppressive - counteract PD-1 blockade

- Myeloid suppressive cells, such as tumor-associated macrophages (TAMs) or myeloid-derived suppressor cells (MDSCs) are key cells in PD-1 resistance and express IL1RAP and are stimulated by IL-1, these cells counteracts PD-1 blockade
- IL-1 upregulate PD-L1 on macrophages and induce downstream factors, such as IL-6, that also contribute to immune suppression in the TME
- IL-1b blockade has been shown to break tolerance to anti-PD-1 in a model for TNBC
- Novartis is exploring PD-1 combinations with canakinumab in Phase III

- **PD-1 antibodies – fastest growing segment in cancer therapy**
- **Strong rationale for combining CAN04 and PD-1 antibodies**



# US phase I clinical trial

- First patient has started
- Combination with checkpoint inhibitor in patients that no longer respond to PD1/PDL-1 therapy
- Primary endpoint safety, secondary endpoints include biomarkers and efficacy
- Indications include NSCLC, HNSCC, malignant melanoma and bladder cancer (18 patients)
- Strong US centers, Coord investigator Prof Roger Cohen, Upenn
- <https://clinicaltrials.gov/ct2/show/NCT04452214>





**Trial designed to advance CAN04 outside chemotherapy combinations**  
**Important step for combining CAN04 with IO and chemotherapy**

A grayscale background image featuring a complex, textured surface, possibly a biological specimen, with a prominent, elongated, and slightly curved structure in the lower right corner. The overall appearance is that of a high-magnification micrograph.

## Untapped possibilities in autoimmune diseases


# CAN10 – New development project

- IL1RAP binding antibody potentially blocking IL-1, IL-33 and IL-36
- Unique anti-inflammatory activity observed in mouse model
- Development focusing on unmet medical need in systemic sclerosis and myocarditis. Disease selection in collaboration with experts based on scientific rational, medical need, development opportunity and competition
- Clinical trials start early 2022



Unique opportunity for CAN10 identified in life-threatening diseases

# CAN10 counteract inflammation in disease model



- Mechanistic proof of concept for IL1RAP blockade in inflammatory driven psoriasis model
- Effect not dependent on IL-1 $\beta$  blockade

**CAN10 has unique anti-inflammatory properties**

The background of the slide is a grayscale photograph of a flower, likely a lily, with its petals and stamens visible. A solid teal horizontal band is superimposed across the middle of the image, containing the title text.

## Milestones and summary

# Significant value inflection points

## Newsflow next 6-9 months

### CAN04

- LPI Phase IIa combination in PDAC
- Phase IIa combination results PDAC and NSCLC
- Next steps PDAC and NSCLC
- Phase IIa biomarker/biopsy results
- New clinical trial in disease/combination outside CANFOUR

### CAN10

- Preclinical progress
- Production development





# Cantargia at a glance



## **Unique immunotherapy antibody CAN04 in phase IIa clinical development**

- Positive interim data set and further phase II milestones during 2020



## **Platform with many potential therapeutic areas**

- Cancer and large number of autoimmune/inflammatory diseases



## **Vision of becoming an important part in future cancer treatments**

- Combination therapy strategy based on synergies with established therapies



## **Highly relevant research within clinically validated mechanisms**

- Focus on opportunities with major unmet medical need



## **Robust patent portfolio – granted IP for therapeutic target IL1RAP and CAN04**

- Global patent families - antibody target in oncology (2032) and CAN04 (2035)



## **Nasdaq Stockholm's main list > 6,000 shareholders and long term investors**

- Market cap: SEK 4.3bn (USD ~480m) (Oct 5, 2020)
- Cash : SEK 458 MSEK (USD 53m) (30 Jun 2020)

